CN109966482A - A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application - Google Patents

A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application Download PDF

Info

Publication number
CN109966482A
CN109966482A CN201910081789.0A CN201910081789A CN109966482A CN 109966482 A CN109966482 A CN 109966482A CN 201910081789 A CN201910081789 A CN 201910081789A CN 109966482 A CN109966482 A CN 109966482A
Authority
CN
China
Prior art keywords
vaccine
foot
hand
mouth disease
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910081789.0A
Other languages
Chinese (zh)
Inventor
冯志伟
赵铁锁
郭胜
贾慧婕
周婷
郭婧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xinxiang Medical University
Original Assignee
Xinxiang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xinxiang Medical University filed Critical Xinxiang Medical University
Priority to CN201910081789.0A priority Critical patent/CN109966482A/en
Publication of CN109966482A publication Critical patent/CN109966482A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention belongs to biomedicine technical field, in particular to a kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application, including synthesis polypeptide vaccine, polypeptide vaccine contain the T cell and B cell epitope of hand-foot-and-mouth disease poison EV71 antigen；Prepare adjuvant；Polypeptide vaccine is configured to mix after solution with adjuvant with volume ratio 1:1.Vaccine injecta of the invention can cause the higher antibody level of hand-foot-and-mouth disease poison EV71, reach preventive effect, and easily preparation.

Description

A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application
Technical field
The invention belongs to biomedicine technical field, in particular to a kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and Preparation method and application.
Background technique
Hand-foot-and-mouth disease is the infectious disease being caused by enterovirus, and the enterovirus for causing hand-foot-and-mouth disease has more than 20 kinds (types), It is wherein most commonly seen with coxsackie virus A 16-type (Cox A16) and enterovirns type 71 (EV 71).The disease mostly occur in 5 years old with There is exanthema vesiculosum or aphtha in lower children, performance stomatalgia, anorexia, low-heat, hand, foot, the positions such as oral cavity, and most infants one week or so Self-healing, a small number of infants can cause the complication such as myocarditis, pulmonary edema, aseptic meningoencephalitis；Individual children with serious disease progression of the disease Fastly, lead to death.Lack effective therapeutic agent at present, mainly still takes symptomatic treatment.
Currently, EV71 type vaccine for hand-foot-mouth disease is the vaccine of China's research and development, which is used to prevent caused by EV71 infection Hand-foot-and-mouth disease is the currently the only inactivated vaccine that can be used for preventing hand-foot-and-mouth disease, in first half of the year official listing in 2016.
In general, vaccine needs the auxiliary of adjuvant that can preferably play a role.Adjuvant refers in advance or infuses simultaneously with antigen Enter the immune response that can enhance body fight original in vivo or changes the nospecific immunity enhancement substance of type of immune response. Adjuvant as nonspecific immunity strengthening agent, be widely used in prophylactic vaccination at assignment system.Adjuvant can be at present It is divided into: biological adjuvant, inorganic compound, synthetic material, organic matter, liposome etc..Currently, the research and development of adjuvant are still people A hot spot studying.
To sum up, vaccine more efficient in order to develop and easily prepared, the application have studied a kind of novel hand-foot-and-mouth disease Malicious EV71 polypeptide vaccine.
Summary of the invention
Vaccine injecta of the invention can cause the higher antibody level of hand-foot-and-mouth disease poison EV71, reach preventive effect, and Easily preparation.
The present invention provides a kind of hand-foot-and-mouth disease polypeptide vaccine, the amino acid sequences of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, the polypeptide vaccine contain hand-foot-and-mouth disease poison The T cell and B cell epitope of EV71 antigen.
A kind of vaccine for hand-foot-mouth disease injection containing above-mentioned hand-foot-and-mouth disease polypeptide vaccine
A kind of preparation method of above-mentioned vaccine for hand-foot-mouth disease injection, comprising the following steps:
S1, synthesis polypeptide vaccine, the amino acid sequence of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT；
S2 prepares adjuvant；
S21 measures following each component by percent by volume: 0.5% Tween 80,0.5% Span85,4.3% flower Oil generation, 94.7% physiological saline, then mix；
DNA sequence dna is added in S22, and being allowed to concentration is 200 μ g/mL, obtains adjuvant, and 4 DEG C save,
Wherein, DNA sequence dna are as follows:
5'-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3'；
In S3, S1 then polypeptide vaccine normal saline is mixed at the solution of 1mg/mL with adjuvant with volume ratio 1:1 It closes, obtains hand-foot-and-mouth disease vaccine injecta.
Preferably, it is mixed in S21 using high pressure homogenizer, pressure 15000-20000kpa.
A kind of application of above-mentioned vaccine for hand-foot-mouth disease injection in prevention hand-foot-and-mouth disease poison EV71.
Compared with prior art, beneficial effects of the present invention:
EV71 polypeptide vaccine prepared by the present invention has good immunogenicity, and adjuvant can effectively improve the immune of antigen Originality, vaccine injecta can cause the higher antibody level of hand-foot-and-mouth disease poison EV71, reach preventive effect, and easily preparation, have Good application prospect.
Detailed description of the invention
Fig. 1 is adjuvant centrifugation front and back comparison diagram in the embodiment of the present invention 1；
Fig. 2 is that immune mouse after 7 days scheme in serum by the detection of EV71 polypeptide antibody for the first time in the embodiment of the present invention 2；
Fig. 3 is that EV71 polypeptide antibody detects and schemes in second immune mouse 1 week and 6 weeks days serum in the embodiment of the present invention 2.
Specific embodiment
The specific embodiment of the present invention is described in detail in 1-3 with reference to the accompanying drawing, it is to be understood that this hair Bright protection scope is not limited by the specific implementation, and reagent involved in embodiment can be obtained by public channel.
Embodiment 1
A kind of hand-foot-and-mouth disease polypeptide vaccine, the amino acid sequence of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, the polypeptide vaccine contain hand-foot-and-mouth disease poison The T cell and B cell epitope of EV71 antigen, commission Qiang Yao Biotechnology Co., Ltd is artificial synthesized, is named as polypeptide vaccine ZJ001。
A kind of vaccine for hand-foot-mouth disease injection comprising above-mentioned hand-foot-and-mouth disease polypeptide vaccine.
A kind of preparation method of above-mentioned vaccine for hand-foot-mouth disease injection, comprising the following steps:
S1, synthesis polypeptide vaccine, the amino acid sequence of polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, as shown in SEQ ID NO.1；
S2 prepares adjuvant；
S21 measures following each component by percent by volume: 0.5% Tween 80,0.5% Span85,4.3% flower Oil generation, 94.7% physiological saline, then mixed with high pressure homogenizer, pressure 16000kpa,；
DNA sequence dna is added in S22, and being allowed to concentration is 200 μ g/mL, obtains adjuvant, 4 DEG C of preservations；The DNA sequence dna entrusts Wuhan Jin Kairui bioengineering Co., Ltd is artificial synthesized and the modification of full thio group.
Wherein, DNA sequence dna are as follows:
5 '-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3 ', as shown in SEQ ID NO.2；
In S3, S1 then polypeptide vaccine normal saline is mixed at the solution of 1mg/mL with adjuvant with volume ratio 1:1 It closes, obtains hand-foot-and-mouth disease vaccine injecta.
The adjuvant of above-mentioned preparation is named as adjuvant ZTS001, for the stability for detecting adjuvant, is placed under 5000r/min and is centrifuged 5min illustrates that the adjuvant has fine stability as a result as shown in Figure 1, centrifugation front and back adjuvant is not layered water-oil separation.
Embodiment 2
A kind of hand-foot-and-mouth disease polypeptide vaccine, the amino acid sequence of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, the polypeptide vaccine contain hand-foot-and-mouth disease poison The T cell and B cell epitope of EV71 antigen, are named as polypeptide vaccine ZJ001.
A kind of vaccine for hand-foot-mouth disease injection comprising above-mentioned hand-foot-and-mouth disease polypeptide vaccine.
A kind of preparation method of above-mentioned vaccine for hand-foot-mouth disease injection, comprising the following steps:
S1, synthesis polypeptide vaccine, the amino acid sequence of polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, as shown in SEQ ID NO.1；；
S2 prepares adjuvant；
S21 measures following each component by percent by volume: 0.5% Tween 80,0.5% Span85,4.3% flower Oil generation, 94.7% physiological saline, then mixed with high pressure homogenizer, pressure be 20000kpa (pressure 15000kpa When homogenizing effect it is consistent with 1 effect of embodiment, therefore do not repeat)；
DNA sequence dna is added in S22, and being allowed to concentration is 200 μ g/mL, obtains adjuvant, 4 DEG C of preservations；
Wherein, DNA sequence dna are as follows:
5 '-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3 ', as shown in SEQ ID NO.2；
In S3, S1 then polypeptide vaccine normal saline is mixed at the solution of 1mg/mL with adjuvant with volume ratio 1:1 It closes, obtains hand-foot-and-mouth disease vaccine injecta.
A kind of application of above-mentioned vaccine injecta in prevention hand-foot-and-mouth disease poison EV71.
For the immune effect for verifying above-mentioned vaccine injecta, following experiment is done: selecting 30 healthy mices, average mark at random It is three groups, one group is blank group, injecting normal saline；One group is control group, injects the polypeptide vaccine of above-mentioned preparation；One group is real Group is tested, the vaccine injecta of above-mentioned preparation is injected；Three groups of injection dosages are 100 μ L/, and are carried out respectively at the 0th day 1st inoculation, the 2nd inoculation of progress in the 7th day.
It is small to three groups before 7 days and the 2nd inoculation before the 1st inoculation and after the 1st inoculation respectively Mouse carries out tail vein and acquires mouse blood, and existing conventional method separating mouse serum is detected in mice serum by Elisa method For the antibody level of EV71 polypeptide.As a result such as Fig. 2:
Wherein, a represents EV71 polypeptide-adjuvant one and exempts from 1 week p < compared with EV71 polypeptide-is without adjuvant feminine gender group in Fig. 2 0.05, significant difference；B represents EV71 polypeptide-adjuvant one and exempts from 1 week p < 0.05 compared with EV71 polypeptide-adjuvant feminine gender group, difference Significantly；C represents EV71 polypeptide-adjuvant one and exempts from 1 week compared with EV71 polypeptide-exempts from 1 week group without adjuvant one, p < 0.05, and difference is aobvious It writes.
As can be known from Fig. 2, with EV71 polypeptide-without adjuvant feminine gender group, EV71 polypeptide-adjuvant feminine gender group and EV71 polypeptide- No adjuvant one is exempted from 1 week group and is compared, and the EV71 antibody level that EV71 polypeptide-adjuvant one is exempted from 1 week group mice serum is significantly raised.It says The activity that there is the bright EV71 polypeptide vaccine that we prepare good stimulation body to generate antibody.It is preceding and independent with not being immunized EV71 polypeptide group is compared, and EV71 polypeptide vaccine joint adjuvant uses the antibody water that can effectively improve EV71 in mice serum It is flat.
After 2nd inoculation after 1 week and 6 weeks, three groups of mouse carry out acquiring mouse blood by tail vein respectively, existing Conventional method separating mouse serum detects the antibody that EV71 polypeptide is directed in mice serum by Elisa method.As a result such as Fig. 3 It is shown:
Wherein in Fig. 3, a represents EV71 polypeptide-adjuvant 2 and exempts from 1 week p < compared with EV71 polypeptide-exempts from 1 week group without adjuvant the 2nd 0.05, significant difference, b represents EV71 polypeptide-adjuvant 2 and exempts from 6 weeks p < 0.05 compared with EV71 polypeptide-exempts from 6 weeks groups without adjuvant 2, poor It is different significant.
As can be known from Fig. 3, compared with independent EV71 polypeptide group, EV71 polypeptide vaccine joint adjuvant can effectively improve small The antibody level of EV71 in mouse serum illustrates that the EV71 polypeptide vaccine that we prepare has good immunogenicity, and adjuvant The immunogenicity that antigen can be effectively improved, has a good application prospect.
It should be noted that the step method used in claims of the present invention is same as the previously described embodiments, in order to anti- It only repeats, description of the invention preferred embodiment, once a person skilled in the art knows basic creative general It reads, then additional changes and modifications can be made to these embodiments.So it includes preferred real that the following claims are intended to be interpreted as It applies example and falls into all change and modification of the scope of the invention.
Obviously, various changes and modifications can be made to the invention without departing from essence of the invention by those skilled in the art Mind and range.In this way, if these modifications and changes of the present invention belongs to the range of the claims in the present invention and its equivalent technologies Within, then the present invention is also intended to include these modifications and variations.
Sequence table
<110>Xinxiang College of Medical Science
<120>a kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application
<140> 201910081789.0
<141> 2019-05-13
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 39
<212> PRT
<213>artificial synthesized
<400> 1
Ala Gly Gly Thr Gly Thr Phe Asp Ser His Pro Pro Tyr Lys Gln Gly
1 5 10 15
Ser Gly Gly Ser Gly Thr Val Cys Pro His Gln Trp Thr Asn Ile Arg
20 25 30
Thr Asn Asn Cys Ala Thr Thr
35
<210> 2
<211> 36
<212> DNA
<213>artificial synthesized
<400> 2
gacgcgcgtc gacgatcgcg aattcgaacg tacgct 36

Claims (5)

1. a kind of hand-foot-and-mouth disease polypeptide vaccine, which is characterized in that the amino acid sequence of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT, the polypeptide vaccine contain hand-foot-and-mouth disease poison EV71 The T cell and B cell epitope of antigen.
2. a kind of vaccine for hand-foot-mouth disease injection containing hand-foot-and-mouth disease polypeptide vaccine described in claim 1.
3. a kind of preparation method of vaccine for hand-foot-mouth disease injection as claimed in claim 2, which is characterized in that including following step It is rapid:
S1, synthesis polypeptide vaccine, the amino acid sequence of the polypeptide vaccine are as follows:
AGGTGTFDSHPPYKQGSGGSGTVCPHQWTNIRTNNCATT；
S2 prepares adjuvant；
S21 measures following each component by percent by volume: 0.5% Tween 80,0.5% Span85,4.3% peanut oil, 94.7% physiological saline, then mixes；
DNA sequence dna is added in S22, and being allowed to concentration is 200 μ g/mL, obtains adjuvant, 4 DEG C of preservations；
Wherein, DNA sequence dna are as follows:
5'-gacgcgcgtcgacgatcgcgaattcgaacgtacgct-3'；
In S3, S1 then polypeptide vaccine normal saline is mixed with volume ratio 1:1 with adjuvant, is obtained at the solution of 1mg/mL Vaccine for hand-foot-mouth disease injection.
4. the preparation method of injection according to claim 3, which is characterized in that carried out in S21 using high pressure homogenizer It mixes, pressure 15000-20000kpa.
5. a kind of application of vaccine for hand-foot-mouth disease injection according to claim 2 in prevention hand-foot-and-mouth disease poison EV71.
CN201910081789.0A 2019-01-28 2019-01-28 A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application Pending CN109966482A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910081789.0A CN109966482A (en) 2019-01-28 2019-01-28 A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910081789.0A CN109966482A (en) 2019-01-28 2019-01-28 A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application

Publications (1)

Publication Number Publication Date
CN109966482A true CN109966482A (en) 2019-07-05

Family

ID=67076746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910081789.0A Pending CN109966482A (en) 2019-01-28 2019-01-28 A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application

Country Status (1)

Country Link
CN (1) CN109966482A (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101717754A (en) * 2009-12-30 2010-06-02 北京科兴生物制品有限公司 Enterovirus type 71 and use thereof
CN101906403A (en) * 2010-05-07 2010-12-08 中国人民解放军军事医学科学院微生物流行病研究所 Enterovirus and application thereof
CN103305475A (en) * 2013-06-07 2013-09-18 中国人民解放军疾病预防控制所 Establishment method and application of enterovirus (EV) 71-gene modification system
CN103374580A (en) * 2012-04-27 2013-10-30 中国医学科学院医药生物技术研究所 Enterovirus 71 (EV 71) Fuyang strain and cDNA (deoxyribonucleic acid) infectious clone of attenuated strain of enterovirus 71 (EV 71) Fuyang strain as well as application of enterovirus 71 (EV 71) Fuyang strain
CN103694318A (en) * 2013-12-31 2014-04-02 党双锁 EV71 (Enterovirus 71) VP1 and RdRp (RNA dependent RNA polymerase) protein specific T cell epitope peptide as well as application thereof
CN104694479A (en) * 2012-07-13 2015-06-10 厦门大学 VP2 antigen neutralizing epitope polypeptide of enterovirus type 71 and use thereof
CN105462937A (en) * 2016-01-21 2016-04-06 武汉大学 Enteroviral chimeric virus-like particle vaccine and preparation method and application thereof
CN106377766A (en) * 2016-10-13 2017-02-08 遵义市第人民医院 EV71-VP1 hand-foot-and-mouth disease polypeptide vaccine, and preparation method and application thereof
CN108486120A (en) * 2018-04-28 2018-09-04 新乡医学院 A kind of novel C pG ODN sequences and its application on melanoma
WO2019008599A1 (en) * 2017-07-03 2019-01-10 Bharat Biotech International Limited A synthetic polypeptide epitope based vaccine composition

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101717754A (en) * 2009-12-30 2010-06-02 北京科兴生物制品有限公司 Enterovirus type 71 and use thereof
CN101906403A (en) * 2010-05-07 2010-12-08 中国人民解放军军事医学科学院微生物流行病研究所 Enterovirus and application thereof
CN103374580A (en) * 2012-04-27 2013-10-30 中国医学科学院医药生物技术研究所 Enterovirus 71 (EV 71) Fuyang strain and cDNA (deoxyribonucleic acid) infectious clone of attenuated strain of enterovirus 71 (EV 71) Fuyang strain as well as application of enterovirus 71 (EV 71) Fuyang strain
CN104694479A (en) * 2012-07-13 2015-06-10 厦门大学 VP2 antigen neutralizing epitope polypeptide of enterovirus type 71 and use thereof
CN103305475A (en) * 2013-06-07 2013-09-18 中国人民解放军疾病预防控制所 Establishment method and application of enterovirus (EV) 71-gene modification system
CN103694318A (en) * 2013-12-31 2014-04-02 党双锁 EV71 (Enterovirus 71) VP1 and RdRp (RNA dependent RNA polymerase) protein specific T cell epitope peptide as well as application thereof
CN105462937A (en) * 2016-01-21 2016-04-06 武汉大学 Enteroviral chimeric virus-like particle vaccine and preparation method and application thereof
CN106377766A (en) * 2016-10-13 2017-02-08 遵义市第人民医院 EV71-VP1 hand-foot-and-mouth disease polypeptide vaccine, and preparation method and application thereof
WO2019008599A1 (en) * 2017-07-03 2019-01-10 Bharat Biotech International Limited A synthetic polypeptide epitope based vaccine composition
CN108486120A (en) * 2018-04-28 2018-09-04 新乡医学院 A kind of novel C pG ODN sequences and its application on melanoma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
RUICHENG WEI等: ""A Dominant EV71-Specific CD4+ T Cell Epitope Is Highly Conserved among Human Enteroviruses", 《PLOS ONE》 *
中国科学技术协会: "《免疫学学科发展报告2014-2015》", 30 April 2016, 中国科学技术出版社 *
曹雪涛、龚非力: "《中华医学百科全书 基础医学 医学免疫学》", 31 December 2018, 中国协和医科大学出版社 *
祝苗 等: "人肠道病毒71型抗原表位的研究进展", 《中国细胞生物学学报》 *
邱昌庆、才学鹏: "《动物疫病基因工程疫苗研究与进展》", 31 December 2005, 中国农业出版社 *

Similar Documents

Publication Publication Date Title
CN110167587A (en) Influenza vaccines
CN100415771C (en) Antigen epitope for exciting human anti-tubercle bacillus protective immunoreaction and its use
CN108912215A (en) Method and composition for dengue virus epitope
JP5848243B2 (en) Immunogenic composition against dengue virus
CN111603556B (en) Preparation and application of novel coronavirus subunit nano vaccine
CN1062605C (en) Escherichia coli vaccine
CN101489589A (en) Immunogenic compositions
US20200246443A1 (en) Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase)
AU2018278927A1 (en) Methods and compositions for dengue virus vaccines
Serrate et al. Transfer of cellular immunity in vivo with immune RNA in an allogeneic murine model
CN101891805A (en) Human enterovirus 71 type specific polypeptide and application thereof
CN101361969A (en) Therapeutic hepatitis b vaccine and preparation method and use thereof
CN109715651A (en) Treating hepatitis B type vaccine
CN109966482A (en) A kind of hand-foot-and-mouth disease polypeptide vaccine, vaccine injecta and its preparation method and application
CN108472356A (en) Fusion protein
CN103189386B (en) Recombinant human immunodeficiency virus（HIV）Envelope antigen albumen and the vaccine containing it
CN107970444A (en) Composite adjuvant and the vaccine containing the composite adjuvant
KR20220014548A (en) Novel epitope of SARS-CoV2 causing coronavirus disease COVID-19 and use thereof
CN105727278B (en) A kind of sore mouth virus recombinant protein antigen vaccine and preparation method thereof
CN101891825B (en) Recombinant fusion proteins of hepatitis B core proteins and tuberculosis antigen or antigen fragments and application thereof
CN1785425B (en) Preparation method of poly peptide vaccine for treating lefteye flounder adenolymphocele
CN112220919A (en) Nano coronavirus recombinant vaccine taking graphene oxide as carrier
CN101838325B (en) Antigen-presenting protein for swines and encoding gene and application thereof
Brown et al. Properties of transplantation antigen present in cell-free extracts of adenovirus-12 tumours
CN109876140A (en) A kind of vaccine and its preparation method and application for treating chronic hepatitis B

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190705